Repligen

RGEN · NASDAQ

$178.88+$2.45 (+1.39%)TodayMarket closed ·
Prev close $176.43

Latest news

  • Press releaseGlobe Newswire

    Repligen Completes Acquisition of BioLife Solutions

  • Press releasePRNewswire

    Freshworks Set to Join S&P SmallCap 600

  • Press releaseBusiness Wire

    BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

  • NewsPiero Cingari

    Nasdaq 100 Enters Correction, SanDisk Sinks Over 50% From Peak: Stock Market Today

  • News

    12 Health Care Stocks Moving In Tuesday's Intraday Session

  • News

    Repligen Q2 Adj. EPS $0.54 Beats $0.45 Estimate, Sales $204.128M Beat $201.483M Estimate

  • Press releaseGlobe Newswire

    Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

  • Press releaseBusiness Wire

    BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

  • NewsVandana Singh

    Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition

  • News

    BioLife Solutions To Be Acquired By Repligen For $31 Per Share In Cash And RGEN Stock At EV Of ~$1.5B

  • Press releaseGlobe Newswire

    Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media

  • NewsPiero Cingari

    Micron Leads Memory-Stock Rally, Nasdaq 100 Tops 29,000: Stock Market Today

  • Press releaseGlobe Newswire

    Repligen Announces Publication of the Company's 2025 Corporate Sustainability Report

  • News

    Repligen Raises FY2026 Adj EPS Guidance from $1.93-$2.01 to $1.97-$2.05 vs $1.97 Est; Lowers FY2026 Sales Guidance from $810.000M-$840.000M to $803.000M-$833.000M vs $827.641M Est

  • News

    Repligen Earnings Preview

  • News

    P/E Ratio Insights for Repligen

  • NewsAvi Kapoor

    This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

  • Press releaseBusiness Wire

    908 Devices Appoints Christopher D. Brown to its Board of Directors

  • NewsVandana Singh

    908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

  • Press releaseBusiness Wire

    Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

  • Press releasePRNewswire

    BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

  • NewsVandana Singh

    Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth

  • NewsLekha Gupta

    Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio?

  • NewsAvi Kapoor

    Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

  • NewsAvi Kapoor

    PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday

  • Press releaseGlobe Newswire

    Repligen Announces Agreement to Acquire Chromatography Innovator Tantti

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.